ABclonal Biotechnology Acquires Yurogen Biosystems

ABclonal Biotechnology Co., Ltd., a global life science tools and services provider, acquires Yurogen Biosystems LLC, a contract research organization dedicated to monoclonal antibody discovery using single-B-cell-based SMabTM platform, to better serve researchers in in vitro diagnostic, and antibody drug and therapeutic discovery markets worldwide. The acquisition comes after the company announced its $93 million Series C funding and marks the first step as the company expands its footprints from academic research reagents production to in vitro diagnostic and pharmaceutical industries.

Genesis Drug Discovery and Development Acquires Integrated Analytical Solutions

Genesis Biotechnology Group® (GBG) and its Contract Research Organization (CRO) arm Genesis Drug Discovery & Development™ (GD3) announced today that it has acquired the Berkeley-based CRO Integrated Analytical Solutions (IAS). Founded in 2004 and located in the San Francisco bay area, IAS is a GxP-compliant CRO providing bioanalytical, drug metabolism, and analytical chemistry services to clients worldwide. “This is our second acquisition in the space of two months as we further expand our presence in the San Francisco bay area, which we see as a market with tremendous growth potential for drug discovery services” said Eli Mordechai, Ph.D., Chief Executive Officer (CEO) of GBG.

NAMSA Acquires American Preclinical Services (APS), Becoming the Preeminent CRO Leader in Interventional and Surgical Preclinical Research Solutions

NAMSA®, the world’s only 100% medical device-focused Contract Research Organization (CRO) providing full continuum development solutions, announced Tuesday its acquisition of Minneapolis-based American Preclinical Services (APS), a full service preclinical CRO. This purchase follows NAMSA’s acquisition of New York-based Syntactx, a leading clinical research services CRO, in January 2021. With the addition of APS’s portfolio of services, NAMSA will further enhance its already robust preclinical solutions by providing Sponsors with a broader range of laboratory models and analysis tools, including innovative surgical instrumentation and several state-of-the-art catheterization labs, imaging capabilities and surgical suites.

Camargo Pharmaceutical Services Acquires Paidion Research

Camargo Pharmaceutical Services, LLC, a leading drug development and commercial partner, announced today it will acquire Paidion Research, Inc., a global pediatric clinical research organization (CRO) based in Durham, N.C. The acquisition is the second in a continuing effort by Camargo to expand services in order to provide leading integrated solutions tailored to the needs of emerging biopharma companies addressing unmet medical needs in rare and complex areas.

Velocity Clinical Research, Backed by NaviMed, Seeks Buyer

The clinical site organization has recruited nearly 10,000 patients for covid-19 studies in total – accelerating business growth tremendously over the last several months.

Veristat Expands Global Service Capability in Biometrics with Acquisition of SQN Clinical

Veristat, a scientific-minded, global clinical research organization (CRO), announced today the expansion of its biometrics capacities and European team by acquiring SQN Clinical, a market-leader in the healthcare arena and one of the largest data-focused specialty contract research companies in Europe. For 25 years, SQN Clinical has successfully supported the needs of global pharmaceutical, biotechnology, medical device, and animal health partners. reporting. The acquisition adds more than 100 professionals, increasing Veristat’s European footprint and bolstering one of Veristat’s most sought after service areas, solidifying its position as a premier provider of world class biometrics solutions.

ICON to Acquire PRA Health Sciences, Creating a World Leader in Healthcare Intelligence and Clinical Research

ICON plc, (NASDAQ: ICLR), a global provider of outsourced drug and device development and commercialisation services to the pharmaceutical, biotechnology and medical device industries, and government and public health organisations, today announced it has entered into a definitive agreement to acquire PRA Health Sciences, Inc. (NASDAQ: PRAH) in a cash and stock transaction valued at approximately $12 billion, with the per share merger consideration consisting of $80 in cash and 0.4125 shares of ICON stock. The consideration represents an approximately 30% premium to PRA’s closing price as of February 23rd, 2021.

Novo Holdings to Acquire Audax’s Altasciences

Novo Holdings A/S, a world-leading life science investor with a focus on long-term, sustainable value creation, announced Monday that it has agreed to acquire Altasciences from Audax Private Equity. Founded in 1992, Altasciences is a leading, fully-integrated, early drug development services platform, providing the pharma and biotech industries with a trusted partner for drug development, from preclinical safety testing through clinical proof-of-concept studies. In the past decade, the company has grown both organically and through acquisitions to have a significant presence in the preclinical safety testing, clinical pharmacology, bioanalytical, CRO services, and CDMO markets.

Altasciences Acquires WCCT Global

Altasciences announced today that they have acquired WCCT Global, Inc., an early stage clinical research organization, or CRO, located in Southern California on the U.S.A.’s West Coast. This acquisition will complement Altasciences’ current clinical operations in Montreal, Canada, and Kansas City, U.S.A., while being in close proximity to their Washington State preclinical facility. The transaction was completed on February 12.

Eurofins Scientific Announces Acquisition of Beacon Discovery, Substantially Expanding Its Integrated Drug Discovery Capabilities and Expertise

Eurofins Scientific (EUFI.PA), a global scientific leader in bioanalytical testing announces the acquisition of Beacon Discovery, a preeminent drug discovery and contract research organization (CRO) focused on G-Protein Coupled Receptor (GPCR) research. Beacon Discovery joins Eurofins Discovery, a market leading CRO with the broadest portfolio of validated in vitro pharmacology, ADMET*, and chemistry services for integrated drug discovery solutions. The transaction is expected to close in the coming weeks upon fulfilment of customary closing conditions.